Advertisement
Organisation › Details
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics AG, founded in 2021, is a clinical-stage biopharmaceutical company leveraging Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics has a portfolio of therapeutic programs based on Sonelokimab (M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. *
Start | 2021-01-01 established (approx) | |
Industry | sonelokimab (M1095/ALX-0761) (IL-17 A/F Nanobody) (MoonLake / Avillion / Merck (DE) / Ablynx) | |
Industry 2 | drug development | |
Person | Santos da Silva, Jorge P. (MoonLake 202107– CEO before nearly 15 years at McKinsey) | |
Person 2 | Bodenstedt, Matthias (MoonLake 202107– CFO before McKinsey) | |
Region | Zug ZG | |
Country | Switzerland | |
Street | 29 Dorfstr. | |
City | 6300 Zug ZG | |
Address record changed: 2023-06-28 | ||
Basic data | Employees | B: 11 to 50 (2022-12-31) |
Currency | USD | |
Profit | -64,506,051,000 (2022-12-31) | |
Cash | 72,114,735,000 (2022-12-31) | |
* Document for »About Section«: MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug. | ||
Record changed: 2023-08-30 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top